Lv41
530 积分 2023-07-28 加入
Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy
5小时前
已完结
Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis
7天前
已完结
Optimization of Benzodiazepinones as Selective Inhibitors of the X-Linked Inhibitor of Apoptosis Protein (XIAP) Second Baculovirus IAP Repeat (BIR2) Domain
17天前
已完结
Inhibitor of Apoptosis Proteins, the Sentinels of Cell Death and Signaling
17天前
已完结
CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers
29天前
已完结
Structure-driven design and precision translation of functionally diverse isatin-based CDK2 inhibitors: Advances in SAR, polypharmacology, and biomarker-guided cancer therapy
3个月前
已完结
Spotlight on 17‐AAG as an Hsp90 inhibitor for molecular targeted cancer treatment
3个月前
已完结
The targeted protein degradation landscape
3个月前
已完结
Development and Optimization of a Scalable Enzymatic Cascade-Carbamate Formation Telescope Process for the Synthesis of CDK2 Selective Candidate Tegtociclib (PF-07104091)
3个月前
已完结
Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance
4个月前
已完结
皖公网安备34019202002308
